Krupa Kamila, Liszcz-Tymoszuk Anna, Czerw Natalia, Czerw Aleksandra, Sygit Katarzyna, Kozłowski Remigiusz, Deptała Andrzej, Badowska-Kozakiewicz Anna
Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Department of Health Economics and Medical Law, Medical University of Warsaw, 01-445 Warsaw, Poland.
Cancers (Basel). 2025 Mar 20;17(6):1039. doi: 10.3390/cancers17061039.
Breast cancer is the most frequently diagnosed neoplasm in the world. It can be classified into four main subtypes, each of them showing differences in the expression of hormone receptor (HR), human epidermal growth factor receptor 2 (HER2), and in cell metabolism. Since 2015, when The U.S. Food and Drug Administration (FDA) approved the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that regulates the cell cycle, treatment of HR+/HER2- BC has become much more effective. Currently, palbociclib, ribociclib, and abemaciclib are more often used both in combination with endocrine therapy as well as in monotherapy. Their application has been extensively verified in many clinical trials such as PALOMA-1,2,3, MONALEESA-1,2,3,7, and MONARCH-1,2,3, which allowed the verification of differences in their effectiveness, dosage, and adverse effects. Subsequent studies, MonarchE and NATALEE, examined the role of these inhibitors as adjuvant therapy, as well as at verifying their safety. Moreover, dalpiciclib is being investigated in HR+/HER2- BC treatment. This article will summarize clinical efficacy, recommendations, and differences in toxicity profile between palbociclib, ribociclib, and abemaciclib and will also discuss the possibility of using dalpiciclib in the treatment of breast cancer.
乳腺癌是全球最常被诊断出的肿瘤。它可分为四种主要亚型，每种亚型在激素受体（HR）、人表皮生长因子受体2（HER2）的表达以及细胞代谢方面都存在差异。自2015年美国食品药品监督管理局（FDA）批准首个调节细胞周期的细胞周期蛋白依赖性激酶4和6（CDK4/6）抑制剂以来，激素受体阳性/人表皮生长因子受体2阴性（HR+/HER2-）乳腺癌的治疗变得更加有效。目前，哌柏西利、瑞博西利和阿贝西利更多地用于联合内分泌治疗以及单药治疗。它们的应用已在许多临床试验中得到广泛验证，如PALOMA-1、2、3，MONALEESA-1、2、3、7，以及MONARCH-1、2、3，这些试验得以验证它们在疗效、剂量和不良反应方面的差异。随后的研究，即MonarchE和NATALEE，考察了这些抑制剂作为辅助治疗的作用，以及验证它们的安全性。此外，达尔西利正在HR+/HER2-乳腺癌治疗中接受研究。本文将总结哌柏西利、瑞博西利和阿贝西利之间的临床疗效、推荐意见以及毒性特征差异，还将讨论使用达尔西利治疗乳腺癌的可能性。
